"ASCO Breakthrough" Held in Japan for the First Time

Group of Global Oncology Leaders Explores Cutting-Edge Advances in Cancer Care
For immediate release
May 17, 2023


Savannah Rogers

View this press release in Japanese here: https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/about-asco/pdf/2023-BT-Media-Advisory-Japanese.pdf 

The American Society of Clinical Oncology (ASCO) will host ASCO Breakthrough, a global oncology meeting in Asia, to shine a light on novel and cutting-edge advances that are transforming cancer care.

Planned and co-hosted by ASCO, the Japan Society of Clinical Oncology, and the Japanese Society of Medical Oncology, along with several other collaborating societies in the Asia Pacific region, ASCO Breakthrough will be held in-person and virtually, and bring together oncology thought leaders, practicing clinicians, med-tech pioneers, novel drug developers, and research trailblazers from around the world. The science and education-driven meeting will cover a broad range of topics impacting cancer care today globally and in Japan as well, including CRISPR and gene editing, artificial intelligence, CAR-T and adoptive cell therapies, and novel therapeutics.

The preliminary keynote and session schedule is available online.

To register for the meeting, please send an email to: mediaregistration@asco.org.



Thursday, August 3 - Saturday, August 5, 2023


PACIFICO Yokohama (1-1-1, Minato Mirai, Nishi-ku, Kanagawa Pref.)

Note: the event will also include a robust online component featuring livestream sessions with Q&A and more for those who want to participate but are unable to attend in person.



Diverse, multidisciplinary experts from around the world will be featured in the meeting program:

  • Hiroshi Mikitani: CEO, Founder, Rakuten (opening remarks and keynote)
  • Maryellen Giger: Distinguished Service Professor of Radiology, Committee on Medical Physics at the University of Chicago (PhD, AN) (keynote speaker)
  • Chris Abbosh: Senior Director, Translational Medicine, AstraZeneca (MD, PhD) (keynote speaker)
  • Takayuki Yoshino: National Cancer Center Hospital East, Director of Japanese Society of Medical Oncology, and Vice-Chairman of Japan Society of Clinical Oncology (MD, PhD)
  • Kohei Shitara: National Cancer Center Hospital East, Japan (MD)
  • Gilberto Lopes: University of Miami Sylvester Comprehensive Cancer Center (MD, FASCO)
  • Melvin Lee Kiang Chua: National Cancer Center Singapore (MBBS, FRCR, PhD, FAMS)


  • Yuichiro Doki: Chair, Japan Society of Clinical Oncology (MD, PhD)
  • Tetsuya Mitsudomi: Specially Appointed Professor of Surgery, Faculty of Medicine, Kinki University (MD)
  • Lillian Siu: Princess Margaret Cancer Center, University of Toronto (MD, FASCO)
  • Peter Yu: Hartford Health Care (MD, Former ASCO President)
  • Tony Mok: The Chinese University of Hong Kong (BMSc, MD, FRCP(C), FASCO)
  • Rebecca Dent: National Cancer Center Singapore (MD)


Approx. 1,000



  • Keynotes by global leaders in the field
  • Multidisciplinary educational sessions addressing the latest in technology, research, and clinical practice, including sessions on precision care using artificial intelligence, CAR-T and adoptive cell therapies, novel therapeutics, and next-generation multiomic technology
  • A special session addressing solutions for the biggest obstacles to patient care in low and middle-resource settings
  • Case-based sessions featuring key opinion leaders focusing on the latest research in specific disease sites
  • Daily rapid abstract sessions featuring short presentations of research on topics that matter most to you
  • Daily poster sessions, with Poster Walks led by experts in the field on key areas of research
  • Daily networking opportunities to collaborate with world-renowned clinicians and investigators putting the research into practice.
  • Simultaneous interpretation from English to Japanese will be offered for the general sessions during ASCO Breakthrough.



ASCO Breakthrough will feature a full-service media center, press releases highlighting noteworthy research, facilitation of interviews, and additional services for reporters. Updated details of the event will be provided in a press release later.

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

About JSCO:

The Japan Society of Clinical Oncology (“JSCO”) is the largest clinical oncology organization in Japan with more than 17,000 members. It covers diverse medical specialties and professional categories that provide a platform for multi-disciplinary medical treatment, research, and human resource development, answering the needs of the times. JSCO has carried out academic research and educational activities from multidisciplinary and cross-professional standpoints, and it continues to actively address issues that are considered too difficult for a specialized academic society covering any single specific field to handle.

About JSMO:

The Japanese Society of Medical Oncology (“JSMO”) was created to contribute to prolonging survival time and improve the quality of life of cancer patients. It also aims to conquering cancer through activities such as (i) spread cancer medical care provided by healthcare workers and medical institutions; (ii) contribute to improving cancer medical levels by educating healthcare workers, including sustainable training of Diplomates certified by the Subspecialty Board of Medical Oncology, JSMO; (iii) contribute to the development of new cancer medical care by supporting the academic activities of its members; (iv) enlighten all citizens by providing correct information about cancer practices and cancer research; and (v) contribute to both, the practice and the research of cancer in the global community by cooperating with overseas associated societies.